(NASDAQ: VTGN) Vistagen Therapeutics's forecast annual revenue growth rate of 423.61% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.63%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.32%.
Vistagen Therapeutics's revenue in 2026 is $790,000.On average, 7 Wall Street analysts forecast VTGN's revenue for 2026 to be $43,225,766, with the lowest VTGN revenue forecast at $31,062,329, and the highest VTGN revenue forecast at $54,081,733. On average, 5 Wall Street analysts forecast VTGN's revenue for 2027 to be $196,239,430, with the lowest VTGN revenue forecast at $47,068,937, and the highest VTGN revenue forecast at $353,611,329.
In 2028, VTGN is forecast to generate $5,225,919,812 in revenue, with the lowest revenue forecast at $5,020,686,570 and the highest revenue forecast at $5,379,646,642.